DoD tests AI models that make it easy to switch from vendors like Palantir
Carladenise Armbrister Edwards, a director at Clover Health Investments Corp. (NASDAQ:CLOV), recently sold 200,000 shares of Class A Common Stock. The healthcare company, currently valued at $1.72 billion, has seen remarkable growth with a 330% return over the past year, according to InvestingPro data. The shares were sold at a weighted average price of $3.61, totaling approximately $722,000. The transactions occurred on March 7, 2025, with prices ranging from $3.54 to $3.66 per share. Following this sale, Edwards holds 273,227 shares in the company. InvestingPro analysis shows the stock currently trades near its Fair Value, with analyst targets ranging from $4 to $6, suggesting potential upside. For deeper insights into insider trading patterns and comprehensive analysis, check out the CLOV Pro Research Report, one of 1,400+ detailed company analyses available on InvestingPro.
In other recent news, Clover Health reported its fourth-quarter 2024 earnings, exceeding analysts’ expectations with an earnings per share (EPS) of -$0.04, compared to the forecasted -$0.07. Despite this positive EPS surprise, the company’s revenue of $330.7 million fell short of the anticipated $348.04 million. For the full year, Clover Health’s insurance revenue grew by 9% to $1.345 billion, and the company achieved an adjusted EBITDA profitability of over $70 million. Looking ahead, Clover Health projects a 37% revenue growth for 2025, with expectations of expanding its Medicare Advantage membership by 30%.
In other developments, Canaccord Genuity raised its price target for Clover Health to $4.50 from $4.20, maintaining a Buy rating. This reflects confidence in the company’s growth strategy, particularly in key markets like Georgia and New Jersey. The analyst firm highlighted Clover Health’s transition from significant losses to positive adjusted EBITDA as a key factor in its positive outlook. Clover Health’s strategic focus on operational efficiencies and market expansion is seen as a path to increased revenue and profit. These recent developments underscore Clover Health’s efforts to improve its financial performance and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.